Life Extension Magazine

Life Extension Magazine May 2004

FDA Approves Deadly Drugs, Delays Lifesaving Therapies

By William Faloon

LE Magazine May 2004

FDA Approves Deadly Drugs, Delays Lifesaving Therapies
References

1. Available at: http://www.kvue.com/shared content/nationworld/nation/012204cccanat painkillers.40e6c221.html. Accessed February 27, 2004.

2. Available at: http://www.fda.gov/bbs/topics/ NEWS/2004/NEW01008.htm. Accessed February 27, 2004.

3. Available at: http://www.fda.gov/ohrms/ dockets/ac/02/agenda/3882A_Draft.doc. Accessed February 27, 2004.

4. Available at: http://www.fdanews.com/ 1_1/dailynews/7334-1.html. Accessed February 27, 2004.

5. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999 Jul; 94(7):1818-22.

6. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol. 1995 Jul;6(1):48-53.

7. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetamino- phen in the absence of alcohol abuse or malnutrition: evidence for increased suscep- tibility to drug toxicity due to cardiopul- monary and renal insufficiency. Hepatology. 1994 May;19(5):1141-8.

8. Clemmesen JO, Ott P, Dalhoff KP, Astrup LB, Tage-Jensen U, Poulsen HE.Recommendations for treatment of paracetamol poisoning. Ugeskr Laegr. 1996 Nov 25; 158(48):6892-5.

9. Conti M, Malandrino S, Magistretti MJ. Protective activity of silipide on liver damage in rodents. Jpn J Pharmacol. 1992 Dec;60(4):315-21.

10. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity.Pharmacol Ther. 1991 Dec;52(3):287-305.

11. Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358-62.

12. Dunjic BS, Axelson J, Ar’Rajab A, Larsson K, Bengmark S. Gastroprotective capability of exogenous phosphatidylcholine in experi- mentally induced chronic gastric ulcers in rats. Scand J Gastroenterol. 1993 Jan;28(1):89-94.

13. Gago-Dominguez M., Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of anal- gesics is a risk factor for renal cell carcino- ma. Br J Cancer. 1999 Oct;81(3):542-8.

14. Graudins A, Aaron CK, Linden CH. Overdose of extended-release acetamino- phen. N Engl J Med. 1995 Jul 20;333(3):196.

15. Jaeschke H, Werner C, Wendel A. Disposition and hepatoprotection by phos- phatidyl choline liposomes in mouse liver. Chem Biol Interact. 1987;64(1-2):127-37.

16. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatmentof early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36(4):277-85.

17. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001 Nov;12(6):690-4.

18. Kind B, Krahenbuhl S, Wyss PA, Meier-Abt PJ. Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning. Schweiz Rundsch Med Prax. 1996 Aug 2; 85(31-32):935-8.

19. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic andnon-alcoholic liver diseases. Adv Pharmacol. 1997;38:601-28.

20. Lieber CS. Alcohol: its metabolism and interaction with nutrients. Annu Rev Nutr. 2000;20:395-430.

21. McLaughlin JK, Blot WJ, Mehl ES, Fraumeni JF Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr. 1985 Dec;69:217-22.

22. Mitchell T, Needham A. Over-the-counter drug is treatment for Alzheimer's. Life Extension. November 2000:50-5.

23. Price LM, Poklis A, Johnson DE. Fatal acetaminophen poisoning with evidence ofsubendocardial necrosis of the heart. J Forensic Sci. 1991 May;36(3):930-5.

24. Richie JP Jr, Lang CA, Chen TS. Acetaminophen-induced depletion of glu- tathione and cysteine in the aging mouse kidney. Biochem. Pharmacol. 1992 Jul 7;44(1):129-35.

25. Siegers CP, Moller-Hartmann W. Cholestyramine as an antidote against paracetamol-induced hepato- and nephro- toxicity in the rat. Toxicol Lett. 1989 May;47(2):179-84.

26. Uhlig S, Wendel A. Glutathione enhance- ment in various mouse organs and protec- tion by glutathione isopropyl ester against liver injury. Biochem Pharmacol. 1990 Jun 15;39(12):1877-81.

27. Werner C, Wendel A. Hepatic uptake and antihepatotoxic properties of vitamin E and liposomes in the mouse. Chem Biol Interact. 1990;75(1):83-92.

28. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of sily- marin, in mice and its association with enhancement of phase II enzymes: implica- tions in cancer chemoprevention. Carcinogenesis. 1999 Nov;20(11):2101-8.

29. Available at: http://www.fda.gov/cder/drug/ analgesics/letter.htm. Accessed February 27, 2004.

30. Available at: http://www.fda.gov/cder/drug/ analgesics/SciencePaper.htm. Accessed February 27, 2004.

31. Available at: http://www.fda.gov/ohrms/ dockets/ac/02/transcripts/3882T1.htm. Accessed February 27, 2004.

32. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001 Nov;12(6):690-4.

33. Available at: http://www.kidney-cancer- symptoms.com. Accessed February 27, 2004.

34. Available at: http://www.kidney-cancer symptoms.com. Accessed February 27, 2004.

35. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985 Aug 1;313(5):292-5.

36. Linet MS, Chow WH, McLaughlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer. 1995 Jul 4;62(1):15-8.

37. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and parac- etamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245-9.

38. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortal- ity. EDTA-ERA Registry Committee. Nephrol Dial Transplant. 1994;9(10):1371-6.

39. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic- induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer. 1999 Oct 15;86(8):1576-82.

40. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med. 1983 Feb 17;308(7):357-62.

41. Rathbun WB, Killen CE, Holleschau AM, Nagasawa HT. Maintenance of hepatic glu- tathione homeostasis and prevention of acetaminophen-induced cataract in mice by L-cysteine prodrugs. Biochem Pharmacol. 1996 May 3;51(9):1111-6.

42. Rathbun WB, Holleschau AM, Cohen JF, Nagasawa HT. Prevention of acetamino- phen- and naphthalene-induced cataract and glutathione loss by CySSME. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):923-9.

43. Nagasawa HT, Shoeman DW, Cohen JF, Rathbun WB. Protection against acetamin- ophen-induced hepatotoxicity by L- CySSME and its N-acetyl and ethyl ester derivatives. J Biochem Toxicol. 1996;11(6):289-95.

44. Zhao C, Shichi H. Prevention of acetamino- phen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. J Ocul Pharmacol Ther. 1998 Aug;14(4):345-55.

45. Qian W, Shichi H. Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. Exp Eye Res. 2000 Dec;71(6):567-74.

46. Qian W, Shichi H. Acetaminophen pro- duces cataract in DBA2 mice by Ah recep- tor-independent induction of CYP1A2. J Ocul Pharmacol Ther. 2000 Aug;16(4):337-44.

47. Available at: http://www.alz.org/AboutAD/ Statistics.asp. Accessed February 27, 2004.

48. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syn- drome. A double-blind, placebo controlled trial. Arzneimittelforschung. 1991 Aug;41(8):773-80.

49. Available at: http://www.lef.org/magazine/ mag2001/july2001_awsi.html. Accessed February 27, 2004.

50. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeri- atric patients with memantine—results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6.

51. Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-con- trolled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.

52. Ferris SH. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2003 Dec;4(12):2305-13.

53. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with mod- erate to severe Alzheimer disease already receiving donepezil: a randomized con- trolled trial. JAMA. 2004 Jan 21;291(3):317-24.

54. Available at: http://www.lef.org/magazine/ mag2001/july2001_report_brain_01.html. Accessed February 27, 2004.

55. Available at: http://www.fda.gov/cder/ogd/ RLD/rld_labeling_approved_June_2001.html. Accessed February 27, 2004.

56. Available at: http://www.fda.gov/cder/foi/ appletter/2001/20690s16ltr.pdf. Accessed February 27, 2004.

57. Available at: http://www.pbs.org/wgbh/ pages/frontline/shows/prescription/. Accessed February 27, 2004.

58. Available at: http://www.commondreams.org/ pressreleases/Dec98/120298c.htm. Accessed February 27, 2004.

59. Available at: http: //www.cato.org/dailys/1- 29-97.html. Accessed February 27, 2004.

60. Available at: http://www.pbs.org/wgbh/ pages/frontline/shows/prescription/hazard/. Accessed February 27, 2004.

61. Available at: http://www.lef.org/magazine/ mag2001/june2001_report_fda.html. Accessed February 27, 2004.

62. Available at: http://www.lef.org/magazine/ mag2000/sep2000_report_rezulin.html. Accessed February 27, 2004.

63. Available at: http://www.life-enhancement.com/ article_template.asp?ID=206. Accessed February 27, 2004.

64. Available at: http://www.lef.org/magazine/ mag2002/jul2002_awsi_01.html. Accessed February 27, 2004.

65. Available at: http://www.lef.org/magazine/ mag2003/mar2003_cover_effects_02.html. Accessed February 27, 2004.

66. Available at: http://www.lef.org/magazine/ mag2000/dec2000_awsi.html. Accessed February 27, 2004.

67. Available at: http://www.newmediaexplorer.org/ chris/2003/07/22/access_to_medical_treatment_act_amta.htm. Accessed February 27, 2004.

68. Available at: http://www.newmediaexplorer.org/ chris/control_tactics.htm. Accessed February 27, 2004.

69. Available at: http://www.lef.org/magazine/ mag2001/sep2001_awsi.html. Accessed February 27, 2004.

70. Available at: http://www.lef.org/magazine/ mag2001/july2001_awsi.html. Accessed February 27, 2004.

71. Available at: http://www.lef.org/featured-articles/track2.html. Accessed February 27, 2004.

72. Available at: http://www.lef.org/magazine/ mag2001/feb2001_awsi.html. Accessed February 27, 2004.

73. Available at: http://www.lef.org/magazine/ mag99/may99-cover.html. Accessed February 27, 2004.

74. Available at: http://tobaccodocuments.org/ pm/2046936740-6743.html. Accessed February 27, 2004.